<DOC>
	<DOCNO>NCT01037062</DOCNO>
	<brief_summary>To provide open-label entecavir subject complete previous blind entecavir trial Japan assess investigator likely benefit additional anti-hepatitis B therapy</brief_summary>
	<brief_title>An Open-Label Rollover Study Entecavir ( BMS-200475 ) Adults With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects complete previous entecavir Phase II study ( AI463047 , 052 053 ) ; ALT ≤ 10 x upper limit normal ; Subjects must wellcompensated liver disease accord ALL follow criterion ; 1 . Prothrombin time ≤ 3 second prolonged compare control value INR ≤ 1.5 2 . Serum albumin ≥ 3 g/dL ( ≥ 30 g/L ) 3 . Serum bilirubin ≤ 2.5 mg/dL ( ≤ 42.75 μmol/L ) Sex Reproductive Status Exceptions Target Disease Exceptions Medical History Concurrent Diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>